Review of EGFR TKIs in metastatic NSCLC, including ongoing trials

Recent clinical trials have demonstrated the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) in the treatment of patients with advanced metastatic non-small cell lung cancer. Most of these recent trials were conducted in patients with EGFR mutation-positive tumou...

Full description

Bibliographic Details
Main Author: Barbara eMelosky
Format: Article
Language:English
Published: Frontiers Media S.A. 2014-09-01
Series:Frontiers in Oncology
Subjects:
Online Access:http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00244/full